Andra AP fonden Buys 18,900 Shares of Boston Scientific Corporation $BSX

Andra AP fonden lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 5,000.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,278 shares of the medical equipment provider’s stock after purchasing an additional 18,900 shares during the quarter. Andra AP fonden’s holdings in Boston Scientific were worth $1,882,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth $26,000. Steph & Co. bought a new stake in Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the last quarter. Financial Consulate Inc. purchased a new position in Boston Scientific in the 3rd quarter worth about $25,000. Finally, United Community Bank lifted its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of research analyst reports. Evercore reduced their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Morgan Stanley dropped their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Truist Financial cut their target price on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Finally, Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Trading Up 1.2%

Shares of Boston Scientific stock opened at $76.68 on Monday. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50. The company’s fifty day simple moving average is $87.31 and its 200-day simple moving average is $95.55. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock has a market capitalization of $113.78 billion, a PE ratio of 39.52, a P/E/G ratio of 1.06 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the company posted $0.70 earnings per share. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.